CoChat

Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis

Open access
Rahman, Md. Obaidur, Kamigaki, Taro, Thandar, Moe Moe, Haruyama, Rei, Yan, Fangyu, Shibamura-Fujiogi, Miho, Khin Maung Soe, July, Islam, Md. Rafiqul, Yoneoka, Daisuke, Miyahara, Reiko, Ota, Erika, Suzuki, Motoi · 2023 · BMJ Open

The DOI matches its Crossref record; 82 of the 95 references it cites were found in a registry or an index; 29 of the 34 sources its claims cite were checked for support.

Abstract

OBJECTIVES: The rapid spread of the SARS-CoV-2 Omicron variant has raised concerns regarding waning vaccine-induced immunity and durability. We evaluated protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant and its sublineages. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Electronic databases and other resources (PubMed, Embase, CENTRAL, MEDLINE, CINAHL PLUS, APA PsycINFO, Web of Science, Scopus, ScienceDirect, MedRxiv and bioRxiv) were searched until December 2022. STUDY ELIGIBILITY CRITERIA: We included studies that assessed the effectiveness of mRNA vaccine booster doses against SARS-CoV-2 infection and severe COVID-19 outcomes caused by the subvariant. DATA EXTRACTION AND SYNTHESIS: Estimates of vaccine effectiveness (VE) at different time points after the third-dose and fourth-dose vaccination were extracted. Random-effects meta-analysis was used to compare VE of the third dose versus the primary series, no vaccination and the fourth dose at different time points. The certainty of the evidence was assessed by Grading of Recommendations, Assessments, Development and Evaluation approach. RESULTS: This review included 50 studies. The third-dose VE, compared with the primary series, against SARS-CoV-2 infection was 48.86% (95% CI 44.90% to 52.82%, low certainty) at ≥14 days, and gradually decreased to 38.01% (95% CI 13.90% to 62.13%, very low certainty) at ≥90 days after the third-dose vaccination. The fourth-dose VE peaked at 14-30 days (56.70% (95% CI 50.36% to 63.04%), moderate certainty), then quickly declined at 61-90 days (22% (95% CI 6.40% to 37.60%), low certainty). Compared with no vaccination, the third-dose VE was 75.84% (95% CI 40.56% to 111.12%, low certainty) against BA.1 infection, and 70.41% (95% CI 49.94% to 90.88%, low certainty) against BA.2 infection at ≥7 days after the third-dose vaccination. The third-dose VE against hospitalisation remained stable over time and maintained 79.30% (95% CI 58.65% to 99.94%, moderate certainty) at 91-120 days. The fourth-dose VE up to 60 days was 67.54% (95% CI 59.76% to 75.33%, moderate certainty) for hospitalisation and 77.88% (95% CI 72.55% to 83.21%, moderate certainty) for death. CONCLUSION: The boosters provided substantial protection against severe COVID-19 outcomes for at least 6 months, although the duration of protection remains uncertain, suggesting the need for a booster dose within 6 months of the third-dose or fourth-dose vaccination. However, the certainty of evidence in our VE estimates varied from very low to moderate, indicating significant heterogeneity among studies that should be considered when interpreting the findings for public health policies. PROSPERO REGISTRATION NUMBER: CRD42023376698.

Overview

CoChat Summary

TL;DR

This systematic review and meta-analysis of 50 real-world studies found that third- and fourth-dose mRNA COVID-19 boosters protect against Omicron infection and symptomatic disease but protection wanes over time. Protection against severe outcomes such as hospitalisation and death remained substantial for at least 6 months, though certainty of evidence ranged from very low to moderate.

Key findings

  • Compared with the primary series, third-dose VE against SARS-CoV-2 infection was 48.86% (95% CI 44.90% to 52.82%, low certainty) at ≥14 days, declined to 38.01% (95% CI 13.90% to 62.13%, very low certainty) at ≥90 days, and fell to 16% (95% CI 12.40% to 19.60%, low certainty) at ≥150 days.
  • Fourth-dose VE against infection peaked at 14–30 days at 56.70% (95% CI 50.36% to 63.04%, moderate certainty) and declined to 22% (95% CI 6.40% to 37.60%, low certainty) at 61–90 days.
  • Compared with no vaccination, third-dose VE against hospitalisation remained stable and was 79.30% (95% CI 58.65% to 99.94%, moderate certainty) at 91–120 days; fourth-dose VE up to 60 days was 67.54% (95% CI 59.76% to 75.33%, moderate certainty) for hospitalisation and 77.88% (95% CI 72.55% to 83.21%, moderate certainty) for death.
  • Third-dose VE compared with no vaccination was 75.84% (95% CI 40.56% to 111.12%, low certainty) against BA.1 infection and 70.41% (95% CI 49.94% to 90.88%, low certainty) against BA.2 infection at ≥7 days.

Methods

  • Systematic review and meta-analysis registered in PROSPERO (CRD42023376698), reported per Cochrane and PRISMA guidelines; databases including PubMed, Embase, CENTRAL, MEDLINE, CINAHL PLUS, APA PsycINFO, Web of Science, Scopus, ScienceDirect, MedRxiv and bioRxiv were searched until December 2022.
  • Included 50 studies (28 case–control, 22 cohort) assessing mRNA vaccine booster effectiveness against SARS-CoV-2 infection and severe COVID-19 outcomes caused by Omicron and its sublineages; no RCTs were identified.
  • Random-effects meta-analysis pooled VE at specific and open-ended time points after third- and fourth-dose vaccination; heterogeneity was assessed with I², publication bias with funnel plots and Egger’s tests, and certainty of evidence with GRADE.

Limitations

  • The paper states that most pooled estimates were based on a limited number of studies with 6-month follow-up after the last booster, so the impact of waning beyond these periods is unknown.
  • The paper states high statistical heterogeneity between studies, predominantly US/European settings, mRNA-vaccine-specific findings, and possible risk of bias, publication bias, and small-study effects; certainty for infection and symptomatic infection was very low to moderate.
  • Evident from the text: fourth-dose analyses were restricted to older people (≥60 years), several time-point estimates came from only one or two studies, and no RCTs were included, so causal inference and generalisability are limited.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1136/bmjopen-2023-076892

Cites

82 of 82 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Figure 1 Study flow chart.
Figure 1 Study flow chart.CC BY-NC · PubMed Central
Figure 2 Third-dose mRNA vaccine effectiveness (VE) against SARS-CoV-2 infection due to Omicron variant, compared with the primary series. REML, Restricted maximum likelihood.
Figure 2 Third-dose mRNA vaccine effectiveness (VE) against SARS-CoV-2 infection due to Omicron variant, compared with the primary series. REML, Restricted maximum likelihood.CC BY-NC · PubMed Central
Figure 3 Third-dose mRNA vaccine effectiveness (VE) against hospitalisation due to Omicron variant, compared with no vaccination. REML, Restricted maximum likelihood.
Figure 3 Third-dose mRNA vaccine effectiveness (VE) against hospitalisation due to Omicron variant, compared with no vaccination. REML, Restricted maximum likelihood.CC BY-NC · PubMed Central
Figure 4 Fourth-dose BNT162b2 vaccine effectiveness (VE) against SARS-CoV-2 infection due to Omicron variant among older people, compared with the third dose. REML Restricted maximum likelihood.
Figure 4 Fourth-dose BNT162b2 vaccine effectiveness (VE) against SARS-CoV-2 infection due to Omicron variant among older people, compared with the third dose. REML Restricted maximum likelihood.CC BY-NC · PubMed Central

Verification

Claims the paper makes

10 Valid · 1 Not valid · 4 Not checked · 96 Own results and interpretations

66 more claims

Create a free account to see all 111 claims and to verify the 2 references still open.

See all claims — free account
  • Probably not a substantial claim. 27
  • It may state two separate claims as one. 16
  • The quote only partly states this claim. 7

Create a free account to see these claims.

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

Each contradiction between two passages listed here was confirmed by an independent check.

2 of 2

Citations

Cites

Show all 82 references

Research works printed but not linked: 3

  1. 10.1016/S0140-6736(21)02183-8/ATTACHMENT/E998365A-8F41-4C9C-997B-8F5A40D3AAD4/MMC1.PDF · doi:10.1016/s0140-6736(21)02183-8/attachment/e998365a-8f41-4c9c-997b-8f5a40d3aad4/mmc1.pdf
  2. 10.1016/S0140-6736(21)02249-2/ATTACHMENT/588607F0-89F7-4E80-8E48-FB7CE8C7F7EC/MMC1.PDF · doi:10.1016/s0140-6736(21)02249-2/attachment/588607f0-89f7-4e80-8e48-fb7ce8c7f7ec/mmc1.pdf
  3. World Health Organization . WHO SAGE roadmap on uses of COVID-19 vaccines in the context of Omicron and substantial population immunity: an approach to optimize the global impact of COVID-19 vaccines at a time when Omicron and its sub-lineages are the dominant circulating variants of concern, based on public health goals, evolving epidemiology, and increasing population-level immunity, first issued 20 October 2020, updated: 13 November 2020, updated: 16 July 2021, update: 21 January 2022, latest update: 30 March 2023. 2023.

Cited by

See all 29

Metadata

Authors
Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., Ota, E., & Suzuki, M.
Affiliations
  • Center for Surveillance, Immunization, and Epidemiologic Research, National Institute of Infectious Diseases, Shinjuku-ku, Tokyo, Japan
  • National Institute of Infectious Diseases (JP)
  • National Center for Global Health and Medicine (JP)
  • Graduate School of Public Health, St Luke's International University, Chuo-ku, Tokyo, Japan
  • University of Rajshahi (BD)
  • St. Luke's International University (JP)
Venue
BMJ Open
Publisher
BMJ
Published
2023-12
Volume
13
Issue
12
Pages
e076892
ISSN
2044-6055 (ISSN-L)
OpenAlex
W4390055705
Cited by
29
References
95
Citations by year
2026: 7 · 2025: 10 · 2024: 12
FWCI
1.37
Type
journal article
Language
en
Open access
Locations
  • BMJ Open (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • HighWire Press Open Archive (submittedVersion)
Funders
Ministry of Health, Labour and Welfare (23HA2005, 23HA2017)
Topics
  • Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
  • Social Sciences › Health › Vaccine Coverage and Hesitancy
  • Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
Keywords
SARS-CoV-2 Omicron subvariants, mRNA vaccines, third dose, vaccine effectiveness, waning immunity, BA.1, BA.2, BA.3, BA.4, BA.5, severe COVID-19 outcomes, breakthrough infection, Omicron subvariants, vaccine durability
MeSH terms
COVID-19, SARS-CoV-2, COVID-19 Vaccines, mRNA Vaccines, Humans

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis. https://app.cochat.ai/papers/10.1136/bmjopen-2023-076892
The paper
Rahman, M. O., Kamigaki, T., Thandar, M. M., Haruyama, R., Yan, F., Shibamura-Fujiogi, M., Khin Maung Soe, J., Islam, M. R., Yoneoka, D., Miyahara, R., Ota, E., & Suzuki, M. (2023). Protection of the third-dose and fourth-dose mRNA vaccines against SARS-CoV-2 Omicron subvariant: a systematic review and meta-analysis. BMJ Open. https://doi.org/10.1136/bmjopen-2023-076892

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.